Reduccin del riesgo cardiovascular : En pacientes con diabetes tipo 2 y enfermedad cardiovascular establecida, se ha demostrado que semaglutide reduce el riesgo de eventos cardiovasculares adversos importantes, incluidos ataques cardacos y accidentes cerebrovasculares
A sister brand of the same medication, called Zepbound, is FDA-approved for chronic weight management
As with other complex diseases, the next era likely involves precision, combination therapypairing antiamyloid agents with treatments aimed at metabolic, inflammatory, vascular, and synaptic pathways
Acute hearing loss in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS)
Accelerate innovation Shorten innovation cycles using AI for demand sensing, compliance and personalization